Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 11/20 | 0.34 |
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.34 |
| ▸ | CDK4 | P11802 | 3/20 | 0.33 |
| ▸ | CCND1 | P24385 | 3/20 | 0.33 |
| ▸ | CCND2 | P30279 | 3/20 | 0.33 |
| ▸ | CCND3 | P30281 | 3/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150107 | 0.80 | CYP11B2 (0.42) | CYP11B2CNR2CDK4CCND1CCND2 | |
| SCHEMBL2577109 | 0.79 | CNR2 (0.40) | CNR2CNR1 | |
| SCHEMBL2429592 | 0.79 | CYP11B2 (0.42) | CYP11B2CDK4CCND1CCND2CCND3 | |
| SCHEMBL2386613 | 0.76 | GPR119 (0.39) | CYP11B2CNR2CDK4CCND1CCND2 | |
| SCHEMBL2582576 | 0.72 | GPR119 (0.41) | — | |
| SCHEMBL12513048 | 0.71 | ALDH1A1 (0.46) | DPP4DPP8DPP7 | |
| SCHEMBL14723056 | 0.71 | ACACB (0.39) | — | |
| SCHEMBL1713467 | 0.70 | GPR119 (0.39) | CYP11B2CDK4CCND1CCND2CCND3 | |
| SCHEMBL1103887 | 0.69 | GPR119 (0.64) | CYP11B2CNR2 | |
| SCHEMBL28170205 | 0.69 | KDM4E (0.50) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114931-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2011-11-02 | — | — | EP | disclosed |
| EP-2383270-A1 | Piperidine GPCR agonists | Prosidion Limited (GB) | 2011-11-02 | — | — | EP | disclosed |
| EP-2383270-A1 | Piperidine GPCR agonists | Prosidion Limited (GB) | 2011-11-02 | — | — | EP | disclosed |
| WO-2011128394-A1 | 3-SUBSTITUTED 5-(PYRROLIDINE-1-CARBONYL) PYRROLIDINE AND ITS DERIVATIVES FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2011-10-20 | — | — | WO | disclosed |
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| EP-2114931-A1 | PIPERIDINE GPCR AGONISTS | Prosidion Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008081205-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | GPR119, GPR27, GLP1R | CYP11B2 1395/4885CNR2 96/4885DPP4 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.